Safety profile of once-weekly subcutaneous semaglutide in a real-world adult population with type 2 diabetes

被引：0
|
作者：
Yale, J. -F. [1 ]
Major-Pedersen, A. [2 ]
Catarig, A. -M. [3 ]
Jain, R. G. [4 ]
Menzen, M. [5 ]
Holmes, P. [6 ]
机构：
[1] McGill Univ, Hlth Ctr, Montreal, PQ, Canada
[2] Novo Nordisk AS, Global Safety, Soborg, Denmark
[3] Novo Nordisk AS, Soborg, Denmark
[4] Novo Nordisk Serv Ctr Private Ltd, Biostat, EPIP Area Whitefield, Mindcomp Tech Pk,2nd Phase, Bangalore, Karnataka, India
[5] Gemeinschaftskrankenhaus Bonn, Innere Med Diabetol, Bonn, Germany
[6] St Georges Med Practice, Yarm Rd, Darlington, Durham, England
来源：
DIABETOLOGIA | 2023年 / 66卷 / SUPPL 1期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
670
引用
收藏
页码：S339 / S340
页数：2
相关论文
共 50 条
  • [41] Semaglutide Once Weekly In Persons with Type 2 Diabetes: Real-World Analysis of the Colombian Diabetes Registry (COL-REAL 1 Study)
    Mario Balcazar, Carlos
    Zambrano, Jose
    Felipe Garcia, Andres
    Eugenia Casanova, Maria
    METABOLISM-CLINICAL AND EXPERIMENTAL, 2021, 116 : 69 - 70
  • [42] Efficacy and safety of once-weekly semaglutide monotherapy vs placebo in subjects with Type 2 diabetes (SUSTAIN 1)
    Sorli, C.
    Harashima, S-I
    Tsoukas, G.
    Unger, J.
    Karsbol, J. D.
    Bain, S.
    DIABETIC MEDICINE, 2017, 34 : 145 - 145
  • [43] Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in subjects with type 2 diabetes (SUSTAIN 1)
    Harashima, Shin-ichi
    Sorli, Christopher
    Tsoukas, George
    Unger, Jeffrey
    Karsbol, Julie Derving
    Hansen, Thomas
    Bain, Stephen
    DIABETES RESEARCH AND CLINICAL PRACTICE, 2016, 120 : S121 - S121
  • [44] Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in subjects with type 2 diabetes (SUSTAIN 1)
    Sorli, C.
    Harashima, S. -I.
    Tsoukas, G.
    Unger, J.
    Karsbol, J. Derving
    Hansen, T.
    Bain, S.
    DIABETOLOGIA, 2016, 59 : S364 - S364
  • [45] Real-world use of once-weekly semaglutide in patients with type 2 diabetes: pooled analysis of data from four SURE studies by baseline characteristic subgroups
    Yale, Jean-Francois
    Bodholdt, Ulrik
    Catarig, Andrei-Mircea
    Catrina, Sergiu
    Clark, Alice
    Ekberg, Neda Rajamand
    Erhan, Umut
    Holmes, Patrick
    Knudsen, Soren Tang
    Liutkus, Joanne
    Sathyapalan, Thozhukat
    Schultes, Bernd
    Rudofsky, Gottfried
    BMJ OPEN DIABETES RESEARCH & CARE, 2022, 10 (02)
  • [46] The effects of once-weekly semaglutide on beta cell function in subjects with type 2 diabetes
    Kapitza, C.
    Dahl, K.
    Jacobsen, J. Bonde
    Axelsen, M. Buhl
    Flint, A.
    DIABETOLOGIA, 2016, 59 : S358 - S359
  • [47] Semaglutide: The Newest Once-Weekly GLP-1 RA for Type 2 Diabetes
    Tuchscherer, Rhianna M.
    Thompson, Angela M.
    Trujillo, Jennifer M.
    ANNALS OF PHARMACOTHERAPY, 2018, 52 (12) : 1224 - 1232
  • [48] Mobile Health Application as a Real-World Data Resource: SelfRecorded Weight Reduction with Once-Weekly Semaglutide
    Bodholdt, Ulrik
    Birot, Sophie
    Catarig, Andrei-Mircea
    Erhan, Umut
    Knop, Filip K.
    DIABETES, 2021, 70
  • [49] Real-World Treatment Patterns Among US Patients With Type 2 Diabetes Mellitus Initiating Treatment With Once Weekly Semaglutide for Diabetes ☆
    Swift, Caroline
    Frazer, Monica
    Sargent, Andrew
    Leszko, Michael
    Buysman, Erin
    Gronroos, Noelle N.
    Alvarez, Sara
    Dunn, Tyler J.
    Noone, Josh
    CLINICAL THERAPEUTICS, 2025, 47 (04) : 277 - 283
  • [50] Study Design and Baseline Profile for Patients with Type 2 Diabetes in the Semaglutide Once-Weekly Randomized Pragmatic Trial (SEPRA)
    Willey, Vincent
    Buse, John B.
    Harty, Brian
    Mitchell, Julie L.
    Soule, Benjamin P.
    Christensen, Helene N.
    Cziraky, Mark J.
    Skibsted, Simon
    DIABETES, 2022, 71
12345